부산대학교 도서관

Laboratory and clinical studies on bacmecillinam (BMPC, KW-1100), a novel penicillin derivative developed by Astra Co., LTD., were carried out with following results.1) Antibacterial activityThe in vitro antibacterial activity of bacmecillinam (BMPC) was tested by the serial microbroth dilution method using MIC 2000 system (Dynateck Co.). The minimum inhibitory concentrations (MICs) of BMPC against 28 standard strains and 658 clinical isolates (S. aureus 50, S. pneumoniae 65, S. faecalis 44, H. influenzae 63, E. coli 48, K. aerogenes 49, C. freundii 49, E. cloacae 49, S. marcescens 50, P. vulgaris 45, P. mirabilis 46, P. rettgeri 50, M morganii 50) were compared with those of ampicillin (ABPC), amoxicillin (AMPC), piperacillin (PIPC), cefaclor (CCL) and pipemidic acid (PPA). Antibacterial activity of BMPC against grampositive cocci was less potent than those of ABPC and AMPC. On the other hand, it was strongest among antibiotics tested against gram-negative rods, especially E. coli, K. pneumoniae, K. aerogenes, C. freundii and E. cloacae.2) Clinical evaluation and adverse reactionThirty three patients with urinary tract infection (acute simple cystitis 29, acute simple pyelonephritis 1, chronic complicated cystitis 1 and chronic complicated pyelonephritis 2) were treated with 80-240mg of BMPC daily for 6-20 days by oral administration. Twenty five of 33 patients responded satisfactory to the treatment and the overall efficacy rate was 75.8%(excellent 10, good 15, fair 2, poor 6). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked up before and after administration of BMPC. In one case, slight transient elevation of S-GOT was observed.